Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) filed a Form 8-K with the Securities and Exchange Commission on January 20, 2026, disclosing a material event.
Corvus Pharmaceuticals, Inc.'s stock currently trades at $21.41 with a market capitalization of $627,777,822. The Healthcare company's stock moved following the disclosure.